Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

ClinicalTrials.gov ID: NCT02713204

Public ClinicalTrials.gov record NCT02713204. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).

Study identification

NCT ID
NCT02713204
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
365 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2016 (Actual)
Primary completion
Oct 3, 2017 (Actual)
Completion
Oct 3, 2017 (Actual)
Last update posted
May 7, 2019

2016 – 2017

United States locations

U.S. sites
87
U.S. states
31
U.S. cities
77
Facility City State ZIP Site status
Regeneron Investigational Site Mobile Alabama — —
Regeneron Investigational Site 1 Phoenix Arizona — —
Regeneron Investigational Site 2 Phoenix Arizona — —
Regeneron Investigational Site 3 Phoenix Arizona — —
Regeneron Investigational Site 1 Tucson Arizona — —
Regeneron Investigational Site 2 Tucson Arizona — —
Regeneron Investigational Site Arcadia California — —
Regeneron Investigational Site Bakersfield California — —
Regeneron Investigational Site Beverly Hills California — —
Regeneron Investigational Site Encino California — —
Regeneron Investigational Site 1 Los Angeles California — —
Regeneron Investigational Site 2 Los Angeles California — —
Regeneron Investigational Site Mountain View California — —
Regeneron Investigational Site Oceanside California — —
Regeneron Investigational Site 1 Palm Desert California — —
Regeneron Investigational Site 2 Palm Desert California — —
Regeneron Investigational Site Palo Alto California — —
Regeneron Investigational Site Poway California — —
Regeneron Investigational Site Redlands California — —
Regeneron Investigational Site Sacramento California — —
Regeneron Investigational Site Santa Maria California — —
Regeneron Investigational Site New London Connecticut — —
Regeneron Investigational Site Altamonte Springs Florida — —
Regeneron Investigational Site Fort Lauderdale Florida — —
Regeneron Investigational Site Lakeland Florida — —
Regeneron Investigational Site Largo Florida — —
Regeneron Investigational Site Miami Florida — —
Regeneron Investigational Site Naples Florida — —
Regeneron Investigational Site Palm Beach Florida — —
Regeneron Investigational Site Tallahassee Florida — —
Regeneron Investigational Site Winter Haven Florida — —
Regeneron Investigational Site Augusta Georgia — —
Regeneron Investigational Site Decatur Georgia — —
Regeneron Investigational Site ‘Aiea Hawaii — —
Regeneron Investigational Site 1 Chicago Illinois — —
Regeneron Investigational Site 2 Chicago Illinois — —
Regeneron Investigational Site Lemont Illinois — —
Regeneron Investigational Site Oak Forest Illinois — —
Regeneron Investigational Site Oak Park Illinois — —
Regeneron Investigational Site Urbana Illinois — —
Regeneron Investigational Site New Albany Indiana — —
Regeneron Investigational Site Des Moines Iowa — —
Regeneron Investigational Site Metairie Louisiana — —
Regeneron Investigational Site 1 Baltimore Maryland — —
Regeneron Investigational Site 2 Baltimore Maryland — —
Regeneron Investigational Site Chevy Chase Maryland — —
Regeneron Investigational Site 1 Boston Massachusetts — —
Regeneron Investigational Site 2 Boston Massachusetts — —
Regeneron Investigational Site Jackson Michigan — —
Regeneron Investigational Site Minneapolis Minnesota — —
Regeneron Investigational Site St Louis Missouri — —
Regeneron Investigational Site Las Vegas Nevada — —
Regeneron Investigational Site Portsmouth New Hampshire — —
Regeneron Investigational Site Edison New Jersey — —
Regeneron Investigational Site Teaneck New Jersey — —
Regeneron Investigational Site Albuquerque New Mexico — —
Regeneron Investigational Site Albany New York — —
Regeneron Investigational Site Bloomfield New York — —
Regeneron Investigational Site Great Neck New York — —
Regeneron Investigational Site Hauppauge New York — —
Regeneron Investigational Site Rochester New York — —
Regeneron Investigational Site Syracuse New York — —
Regeneron Investigational Site Asheville North Carolina — —
Regeneron Investigational Site Charlotte North Carolina — —
Regeneron Investigational Site Durham North Carolina — —
Regeneron Investigational Site Cleveland Ohio — —
Regeneron Investigational Site Dublin Ohio — —
Regeneron Investigational Site Portland Oregon — —
Regeneron Investigational Site Camp Hill Pennsylvania — —
Regeneron Investigational Site Huntingdon Pennsylvania — —
Regeneron Investigational Site Ladson South Carolina — —
Regeneron Investigational Site Rapid City South Dakota — —
Regeneron Investigational Site Germantown Tennessee — —
Regeneron Investigational Site Knoxville Tennessee — —
Regeneron Investigational Site Nashville Tennessee — —
Regeneron Investigational Site Abilene Texas — —
Regeneron Investigational Site 1 Austin Texas — —
Regeneron Investigational Site 2 Austin Texas — —
Regeneron Investigational Site Dallas Texas — —
Regeneron Investigational Site 1 Fort Worth Texas — —
Regeneron Investigational Site 2 Fort Worth Texas — —
Regeneron Investigational Site Harlingen Texas — —
Regeneron Investigational Site Houston Texas — —
Regeneron Investigational Site The Woodlands Texas — —
Regeneron Investigational Site Willow Park Texas — —
Regeneron Investigational Site Salt Lake City Utah — —
Regeneron Investigational Site Madison Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02713204, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2019 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02713204 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →